Dr. Abud Bakri

Like, if we knew that it would work, I would love to give them an infusion of BPC-157, and that's the future I could see happening, but we need data.

There's multiple patents on BPC-157, depending on which salt they're in.

The patent has been passed around a couple of times through different places.

Unfortunately, the company that had the patent under the Pliva got acquired by Teva.

Teva is this generic pharmaceutical company, and they make, you know, Adderall.

So they're making tons of money making Adderall.

They don't really care about BPC-157.

So they have one of the patents.

The other patent expires in like 10 years.

I think Sikorek still has it.

Dr. Sikorek is the guy behind BPC-157.

He's in Croatia.

He's in Croatia, yeah.

Would Teva sell the patent?

I'm sure they would if someone made an offer.

The problem is I don't see the purpose of even having the patent because you can add on one chain to the amino acid.

This is the problem with peptides.

This is what Eli Lilly is coming into when it comes to making RETA is that patent laws for peptides kind of suck.

Because you can add on one amino acid, you can modify one thing on it, and suddenly it's a different compound.

This is true for other pharmaceuticals.